1. General

All content published on this website and associated channels by Sequela Research (“Sequela”, “we”, “us”) is provided for informational and educational purposes only. Nothing on this website constitutes, or should be construed as, investment advice, a solicitation, a personal recommendation, or an offer or invitation to buy or sell any security, financial instrument, or asset.

Readers and subscribers should not rely on any content published by Sequela Research as the sole or primary basis for any investment, financial, clinical, or business decision. All such decisions should be made following independent research and, where appropriate, consultation with a qualified financial adviser, legal counsel, or medical professional.

2. Regulatory Status

Sequela Research is not authorised or regulated by the Financial Conduct Authority (FCA) in the United Kingdom, the European Securities and Markets Authority (ESMA) or any national competent authority within the European Union, the U.S. Securities and Exchange Commission (SEC) or the Financial Industry Regulatory Authority (FINRA) in the United States, or any other financial regulatory body in any jurisdiction.

Content published by Sequela Research does not constitute regulated investment research, a regulated investment recommendation, or a personal recommendation for the purposes of:

The UK Financial Services and Markets Act 2000 (FSMA) or the UK Market Abuse Regulation (UK MAR)
EU Directive 2014/65/EU (MiFID II) or EU Regulation 596/2014 (MAR)
The U.S. Investment Advisers Act of 1940 or any applicable U.S. federal or state securities laws

All content is published as general commentary and independent analysis in the public interest. Readers in regulated jurisdictions are responsible for determining whether and how this content may be used in compliance with applicable local laws and regulations.

3. Conflicts of Interest & Independence

Sequela Research is committed to transparency and editorial independence. For each article or report published, any material conflicts of interest held by the author(s) at the time of publication will be disclosed within that piece of content. This may include, but is not limited to:

Ownership of securities or financial instruments referenced in the content
Commercial or advisory relationships with the company or the company’s product being discussed

Sequela Research does not accept payment from any company, individual, or organisation in exchange for favourable coverage, analysis, or opinion. All views expressed are those of the author(s) and are independent of any third-party influence.

Note: Article-level conflict disclosures supplement but do not replace this general policy. Readers should review both this page and the relevant article-level disclosure before relying on any content.

4. Forward-Looking Statements & Projections

Certain content published by Sequela Research may contain forward-looking statements, projections, estimates, or opinions about future events, including but not limited to:

Regulatory approval probabilities and timelines
Clinical trial outcomes and data interpretations
Market adoption rates and commercial forecasts
Drug pricing and reimbursement assumptions

Such statements reflect the author’s independent analytical judgement at the time of writing, based on publicly available information. They are subject to material uncertainty and may differ significantly from actual outcomes. They should not be interpreted as forecasts, guarantees, or predictions of future performance.

Any modelling or analytical frameworks used by Sequela Research represent proprietary methodologies and are disclosed where relevant within individual pieces of content. The use of historical analogues or surrogate programmes to inform projections carries inherent limitations and should be interpreted with appropriate caution.

5. Clinical & Scientific Content

Where Sequela Research publishes analysis of clinical trial data, scientific research, or regulatory matters, the following limitations apply:

Cross-trial comparisons are inherently limited by differences in study design, patient populations, endpoints, follow-up periods, and statistical methodologies. Such comparisons should be interpreted with caution and do not constitute clinical equivalence assessments.
Analysis of regulatory approval likelihood is based solely on publicly available data and does not reflect any non-public information, communication with regulatory authorities, or privileged access to regulatory submissions.
Where safety data is discussed, readers should be aware that small clinical trial datasets may not detect rare but serious adverse events. Conclusions may change materially as larger, longer-term datasets accumulate.
Content on this website is not intended as medical advice and should not be used as the basis for clinical or therapeutic decisions by patients, caregivers, or healthcare professionals.

6. Limitation of Liability

To the fullest extent permitted by applicable law, Sequela Research and its author(s) accept no liability for any loss, damage, cost, or expense — whether direct, indirect, consequential, or otherwise — arising from or in connection with:

Reliance on any content published on this website
Investment or business decisions made on the basis of such content
Any errors, omissions, or inaccuracies in the content
Any interruption, delay, or failure of this website or its content

Nothing in this disclaimer excludes or limits liability that cannot be excluded or limited under applicable law.

7. Third-Party Sources & Data

Content published by Sequela Research may reference or cite third-party sources including company disclosures, regulatory filings, academic publications, and press releases. While we endeavour to ensure the accuracy of information drawn from such sources, Sequela Research does not warrant the accuracy, completeness, or timeliness of any third-party data and is not responsible for errors or omissions in such sources.

References to third-party sources do not constitute an endorsement of those sources or any views expressed therein.

8. Currency of Information

Each piece of content published by Sequela Research reflects information available as of its stated publication date and has not been updated unless explicitly indicated. The biotech and pharmaceutical landscape, regulatory environment, and financial markets are subject to rapid change. Content that was accurate at the time of publication may no longer reflect current conditions.

Readers are encouraged to verify the currency of any information before relying on it and to consult up-to-date sources for the most recent developments.

9. Intellectual Property

All content published by Sequela Research, including but not limited to articles, analyses, data visualisations, and frameworks, is the intellectual property of Sequela Research unless otherwise stated. Reproduction, distribution, or commercial use of any content without prior written permission is prohibited.

Content may be shared for non-commercial purposes provided that Sequela Research is clearly attributed as the source and a link to the original content is included.

10. Questions & Contact

If you have any questions about this disclaimer or the content published by Sequela Research, please contact us via the Contact page on this website.

Sequela Research reserves the right to update or amend this disclaimer at any time. The date at the top of this page reflects the most recent revision. Continued use of this website following any amendment constitutes acceptance of the revised terms.